Influenza roadmap:
Vaccines
Roadmap for the development of candidate vaccines for influenza
Download Influenza-vaccine-development-roadmap4
Inactivated vaccines
Inactivated vaccines
Research Question
- Fast production of highly immunogenic inactivated vaccines for novel
strains
Research Gaps and Challenges
- Low immune response
- Low speed of production for novel strains
- Rapid production of vaccine due to the limitation of virus growth on
eggs - Inactivated vaccines do not allow for mass application and need to
match the circulating strain to confer reasonable protection
Solution Routes
- Development of a suitable tissue culture system for production
- Strategies to increase mucosal immune responses after inactivated
vaccines - Novel/improved adjuvants
- Ability to overcome Maternally Derived Antibodies (MDA) interference.
- Build on improvement in humans research
Dependencies
- Identification of best vaccination strategies (Mucosal vs systemic protection vaccine for the whole year or specific period of time or season?)
State Of the Art
- Mostly egg based inactivated vaccines. Egg manufacturing platform is
costly, and supply is limited - Currently the inactivated vaccine provides suboptimal immunity in birds with maternally derived antibodies (MDA), but birds are vaccinated in ovo and day old in the hatchery
Projects
What activities are planned or underway?
Protect wildlife from livestock diseases.
Planned Completion date 07/10/2022
Participating Country(s):
Netherlands
Dynamics of sustainability in integrated agriculture : aquaculture systems in the Mekong Delta
Planned Completion date 21/10/2024
Participating Country(s):
Netherlands